Cargando…
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204613/ https://www.ncbi.nlm.nih.gov/pubmed/32300051 http://dx.doi.org/10.1136/jitc-2020-000878 |
| _version_ | 1783530082584756224 |
|---|---|
| author | Ascierto, Paolo Antonio Fox, Bernard A Urba, Walter J Anderson, Ana Carrizosa Atkins, Michael B Borden, Ernest C Brahmer, Julie R Butterfield, Lisa H Cesano, Alessandra Chen, Daniel S de Gruijl, Tanja D Dillman, Robert O Drake, Charles G Emens, Leisha A Gajewski, Thomas F Gulley, James L Stephen Hodi Jr, F Hwu, Patrick Kaufman, David Kaufman, Howard L Lotze, Michael T McNeel, Douglas G Margolin, Kim A Marincola, Francesco M Mastrangelo, Michael J Maus, Marcela V Parkinson, David R Romero, Pedro J Sondel, Paul M Spranger, Stefani Sznol, Mario Weiner, George J Wigginton, Jon M Weber, Jeffrey S |
| author_facet | Ascierto, Paolo Antonio Fox, Bernard A Urba, Walter J Anderson, Ana Carrizosa Atkins, Michael B Borden, Ernest C Brahmer, Julie R Butterfield, Lisa H Cesano, Alessandra Chen, Daniel S de Gruijl, Tanja D Dillman, Robert O Drake, Charles G Emens, Leisha A Gajewski, Thomas F Gulley, James L Stephen Hodi Jr, F Hwu, Patrick Kaufman, David Kaufman, Howard L Lotze, Michael T McNeel, Douglas G Margolin, Kim A Marincola, Francesco M Mastrangelo, Michael J Maus, Marcela V Parkinson, David R Romero, Pedro J Sondel, Paul M Spranger, Stefani Sznol, Mario Weiner, George J Wigginton, Jon M Weber, Jeffrey S |
| author_sort | Ascierto, Paolo Antonio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7204613 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72046132020-05-12 Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Ascierto, Paolo Antonio Fox, Bernard A Urba, Walter J Anderson, Ana Carrizosa Atkins, Michael B Borden, Ernest C Brahmer, Julie R Butterfield, Lisa H Cesano, Alessandra Chen, Daniel S de Gruijl, Tanja D Dillman, Robert O Drake, Charles G Emens, Leisha A Gajewski, Thomas F Gulley, James L Stephen Hodi Jr, F Hwu, Patrick Kaufman, David Kaufman, Howard L Lotze, Michael T McNeel, Douglas G Margolin, Kim A Marincola, Francesco M Mastrangelo, Michael J Maus, Marcela V Parkinson, David R Romero, Pedro J Sondel, Paul M Spranger, Stefani Sznol, Mario Weiner, George J Wigginton, Jon M Weber, Jeffrey S J Immunother Cancer Editorial BMJ Publishing Group 2020-04-16 /pmc/articles/PMC7204613/ /pubmed/32300051 http://dx.doi.org/10.1136/jitc-2020-000878 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Editorial Ascierto, Paolo Antonio Fox, Bernard A Urba, Walter J Anderson, Ana Carrizosa Atkins, Michael B Borden, Ernest C Brahmer, Julie R Butterfield, Lisa H Cesano, Alessandra Chen, Daniel S de Gruijl, Tanja D Dillman, Robert O Drake, Charles G Emens, Leisha A Gajewski, Thomas F Gulley, James L Stephen Hodi Jr, F Hwu, Patrick Kaufman, David Kaufman, Howard L Lotze, Michael T McNeel, Douglas G Margolin, Kim A Marincola, Francesco M Mastrangelo, Michael J Maus, Marcela V Parkinson, David R Romero, Pedro J Sondel, Paul M Spranger, Stefani Sznol, Mario Weiner, George J Wigginton, Jon M Weber, Jeffrey S Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_full | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_fullStr | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_full_unstemmed | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_short | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 |
| title_sort | insights from immuno-oncology: the society for immunotherapy of cancer statement on access to il-6-targeting therapies for covid-19 |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204613/ https://www.ncbi.nlm.nih.gov/pubmed/32300051 http://dx.doi.org/10.1136/jitc-2020-000878 |
| work_keys_str_mv | AT asciertopaoloantonio insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT foxbernarda insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT urbawalterj insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT andersonanacarrizosa insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT atkinsmichaelb insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT bordenernestc insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT brahmerjulier insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT butterfieldlisah insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT cesanoalessandra insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT chendaniels insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT degruijltanjad insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT dillmanroberto insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT drakecharlesg insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT emensleishaa insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT gajewskithomasf insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT gulleyjamesl insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT stephenhodijrf insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT hwupatrick insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT kaufmandavid insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT kaufmanhowardl insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT lotzemichaelt insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT mcneeldouglasg insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT margolinkima insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT marincolafrancescom insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT mastrangelomichaelj insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT mausmarcelav insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT parkinsondavidr insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT romeropedroj insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT sondelpaulm insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT sprangerstefani insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT sznolmario insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT weinergeorgej insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT wiggintonjonm insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 AT weberjeffreys insightsfromimmunooncologythesocietyforimmunotherapyofcancerstatementonaccesstoil6targetingtherapiesforcovid19 |